Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.






21st Austria weekly - voestalpine, Sanochemia (16/12/2019)

22.12.2019

voestalpine: In the current business year, non-recurring effects in an amount of Euro 360 mn will negatively influence the result of voestalpine AG. This charge essentially contains write-offs due to impairment of assets and is the result of the analysis of possible effects of the changed global economic conditions on the main business segments of voestalpine, announced in the last outlook. All non-recurring effects reduce EBIT, but Euro 80 mn affect EBITDA as well. From today's perspective, the Management Board therefor expects EBIT for the current business year 2019/20 to be just positive and operating profit (EBITDA) to be in a range of around Euro 1.2 bn. In view of this earnings expectation, the management board will propose to the supervisory board to submit a resolution to the Annual General Meeting to lower the dividend for the business year 2019/20 in comparison to the last business year. The proposal will take the dividend yield as well as the payout ratio into account.
voestalpine: weekly performance: 0.08%

Sanochemia: In connection with the ad hoc publication of December 9, 2019 regarding an impending bankruptcy of the company, the Management Board of Sanochemi Pharmaceuticals AG (ISIN AT0000776307) announced that the application for the opening of a restructuring process without self-administration was brought to the court.
Sanochemia: weekly performance: -1.86%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (16/12/2019)


Partners









latest 21st Austria

21st Austria weekly - voestalpine, Sanochemia (16/12/2019)


22.12.2019, 1483 Zeichen



voestalpine: In the current business year, non-recurring effects in an amount of Euro 360 mn will negatively influence the result of voestalpine AG. This charge essentially contains write-offs due to impairment of assets and is the result of the analysis of possible effects of the changed global economic conditions on the main business segments of voestalpine, announced in the last outlook. All non-recurring effects reduce EBIT, but Euro 80 mn affect EBITDA as well. From today's perspective, the Management Board therefor expects EBIT for the current business year 2019/20 to be just positive and operating profit (EBITDA) to be in a range of around Euro 1.2 bn. In view of this earnings expectation, the management board will propose to the supervisory board to submit a resolution to the Annual General Meeting to lower the dividend for the business year 2019/20 in comparison to the last business year. The proposal will take the dividend yield as well as the payout ratio into account.
voestalpine: weekly performance: 0.08%

Sanochemia: In connection with the ad hoc publication of December 9, 2019 regarding an impending bankruptcy of the company, the Management Board of Sanochemi Pharmaceuticals AG (ISIN AT0000776307) announced that the application for the opening of a restructuring process without self-administration was brought to the court.
Sanochemia: weekly performance: -1.86%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (16/12/2019)



BSN Podcasts
Christian Drastil: Wiener Börse Plausch

kapitalmarkt-stimme.at daily voice 4/365: Vermögenssteuern - eine Einordnung von Finanzminister Gunter Mayr




 

Bildnachweis

Aktien auf dem Radar:Warimpex, Kapsch TrafficCom, Amag, Frequentis, Austriacard Holdings AG, Rosenbauer, EVN, FACC, OMV, SBO, AT&S, Telekom Austria, Athos Immobilien, Cleen Energy, Gurktaler AG VZ, Josef Manner & Comp. AG, Marinomed Biotech, Wolford, Polytec Group, Semperit, Porr, Zumtobel, RHI Magnesita, EuroTeleSites AG, Flughafen Wien, Kostad, Oberbank AG Stamm, BKS Bank Stamm, Pierer Mobility, UBM, Strabag.


Random Partner

Evotec
Evotec ist ein Wirkstoffforschungs- und -entwicklungsunternehmen, das in Forschungsallianzen und Entwicklungspartnerschaften mit Pharma- und Biotechnologieunternehmen, akademischen Einrichtungen, Patientenorganisationen und Risikokapitalgesellschaften Ansätze zur Entwicklung neuer pharmazeutischer Produkte vorantreibt.

>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten